Who is sponsoring NCT05613738?

NCT05613738 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT05613738?

Interventions in NCT05613738: 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01, 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01, 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01.

What condition does NCT05613738 study?

NCT05613738 studies Metastatic Castration-resistant Prostate Cancer.

Is NCT05613738 still recruiting?

NCT05613738 is currently recruiting now. Last updated 10 July 2024.

Last reviewed 2024-07-10 · How we verify

NCT05613738

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer

Recruiting now NA Last updated 10 July 2024

What this trial tests

NA trial testing 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 in Metastatic Castration-resistant Prostate Cancer in 9 participants. Currently enrolling.

Timeline

23 November 2022

Primary endpoint
30 June 2025

15 November 2025

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	23 November 2022
Primary completion	30 June 2025
Estimated completion	15 November 2025
Sites	1 location across China

Drugs / interventions tested

1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 — full drug profile →
1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 — full drug profile →
2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 — full drug profile →

Conditions studied

Metastatic Castration-resistant Prostate Cancer — all drugs for Metastatic Castration-resistant Prostate Cancer →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 80, male only, with Metastatic Castration-resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot study to assess the safety and measure image-based absorbed dose of 177Lu-PSMA-EB-01, a new PSMA-specific radiopharmaceutical, in patients with metastatic castration resistant prostate cancer (mCRPC) who will undergo radioligand therapy (RLT). All patients underwent 68Ga-PSMA and 18F-FDG PET/CT for selection and were randomly divided into three groups of 3 people each.The three groups received an approximately 1.11 GBq (30mCi), 1.85 GBq (50 mCi) and 2.59 GBq (70mCi) of 177Lu-PSMA-EB-01 up to 2 cycles, respectively.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Peptide Drug Conjugates and Their Role in Cancer Therapy.
Heh E, Allen J, Ramirez F, Lovasz D, et al · · 2023 · cited 54× · PMID 36614268 · DOI 10.3390/ijms24010829
A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [<sup>177</sup>Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer.
Zang J, Wang G, Zhao T, Liu H, et al · · 2024 · cited 19× · PMID 37864592 · DOI 10.1007/s00259-023-06470-3

Verify or expand the search:

Other recruiting trials for Metastatic Castration-resistant Prostate Cancer

Currently open trials in the same condition.

NCT07142551 — Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response · Phase 2 · recruiting
NCT07288359 — Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and · Phase 1, PHASE2 · recruiting
NCT07244341 — A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer ( · Phase 1 · recruiting
NCT07213674 — A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic · Phase 3 · recruiting
NCT07189403 — A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resist · Phase 1 · recruiting

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05613738 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 10 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05613738.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing